Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 11/20 | 0.35 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.35 |
| ▸ | HTR6 | P50406 | 2/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30659408 | 1.00 | PDK2 (0.38) | PDK2PDK4DRD2KDM4EALDH1A1 | |
| SCHEMBL3601425 | 0.79 | PDK2 (0.38) | PDK2PDK4DRD2KDM4EALDH1A1 | |
| SCHEMBL14444683 | 0.79 | BRD4 (0.38) | PDK2PDK4DRD2KDM4EALDH1A1 | |
| SCHEMBL1161295 | 0.79 | MEN1 (0.32) | PDK2PDK4KDM4EALDH1A1 | |
| SCHEMBL13672076 | 0.79 | KDM4E (0.38) | PDK2PDK4DRD2KDM4EALDH1A1 | |
| SCHEMBL16792465 | 0.79 | PDK2 (0.38) | PDK2PDK4DRD2KDM4EALDH1A1 | |
| SCHEMBL17200471 | 0.78 | CRBN (0.35) | ALDH1A1BRD4CREBBPPOLB | |
| SCHEMBL4968292 | 0.77 | DRD2 (0.36) | PDK2PDK4DRD2KDM4EALDH1A1 | |
| SCHEMBL7967862 | 0.76 | ALOX5 (0.41) | PDK2PDK4DRD2KDM4EALDH1A1 | |
| SCHEMBL25343286 | 0.75 | PDE3B (0.35) | KDM4EALDH1A1SMN1; SMN2PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250382285-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | C4 THERAPEUTICS, INC. (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250368631-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | C4 THERAPEUTICS, INC. (US) | 2025-12-04 | — | — | US | disclosed |
| US-12421220-B2 | Bicyclic-substituted glutarimide cereblon binders | C4 THERAPEUTICS, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| EP-4539849-A1 | COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 | C4 Therapeutics, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| US-20250122179-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | C4 THERAPEUTICS, INC. (US) | 2025-04-17 | — | — | US | disclosed |
| US-20250121070-A1 | COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 | C4 THERAPEUTICS, INC. (US) | 2025-04-17 | — | — | US | disclosed |
| EP-4536656-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | C4 Therapeutics, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| WO-2023244764-A1 | COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 | C4 THERAPEUTICS, INC. (US) | 2023-12-21 | — | — | WO | disclosed |
| WO-2023244764-A1 | COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 | C4 THERAPEUTICS, INC. (US) | 2023-12-21 | — | — | WO | disclosed |
| WO-2023239750-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | C4 THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| US-7141562-B2 | Substituted benzoxazinones and uses thereof | ROCHE PALO ALTO LLC (US) | 2006-11-28 | — | — | US | disclosed |
| EP-1694656-A1 | BENZOXAZINE DERIVATIVES AND USES THEREOF | F.HOFFMANN-LA ROCHE AG (CH) | 2006-08-30 | — | — | EP | disclosed |
| EP-1562918-A1 | SUBSTITUTED BENZOXAZINONES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2005-08-17 | — | — | EP | disclosed |
| WO-2005058847-A1 | BENZOXAZINE DERIVATIVES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-30 | — | — | WO | disclosed |
| US-20050130962-A1 | Benzoxazine derivatives and uses thereof | BERGER JACOB (US) | 2005-06-16 | — | — | US | disclosed |
| US-20050124613-A1 | Benzoxazine derivatives and uses thereof | ROCHE PALO ALTO LLC | 2005-06-09 | — | — | US | disclosed |
| US-6867204-B2 | Benzoxazine derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2005-03-15 | — | — | US | disclosed |
| WO-2004041792-A1 | SUBSTITUTED BENZOXAZINONES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2004-05-21 | — | — | WO | disclosed |
| US-20040092512-A1 | Substituted benzoxazinones and uses thereof | ROCHE PALO ALTO LLC | 2004-05-13 | — | — | US | disclosed |
| US-20030232825-A1 | Benzoxazine derivatives and uses thereof | ROCHE PALO ALTO LLC | 2003-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250368631-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | CRBN, STUB1, CUL1 | PDK2 2244/4885PDK4 2552/4885DRD2 2732/4885 |
| US-20250122179-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | CRBN, STUB1, CUL1 | PDK2 2244/4885PDK4 2552/4885DRD2 2732/4885 |
| US-20050130962-A1 | Benzoxazine derivatives and uses thereof | F12, HAX1, CYP4X1 | PDK2 1784/4885PDK4 1536/4885DRD2 1295/4885 |
| US-20030232825-A1 | Benzoxazine derivatives and uses thereof | CYP3A5, CYP4X1, XDH | PDK2 1349/4885PDK4 1271/4885DRD2 1352/4885 |
| US-20250121070-A1 | COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 | SMARCA2, SMARCE1, SMARCA1 | PDK2 2912/4885PDK4 3825/4885DRD2 3913/4885 |
| US-20050124613-A1 | Benzoxazine derivatives and uses thereof | XDH, CYP4X1, CYP2C9 | PDK2 395/4885PDK4 565/4885DRD2 983/4885 |
| US-20040092512-A1 | Substituted benzoxazinones and uses thereof | CYP4X1, CYP3A5, CYP2D6 | PDK2 976/4885PDK4 860/4885DRD2 1395/4885 |
| US-20250382285-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | CRBN, STUB1, CUL1 | PDK2 2244/4885PDK4 2552/4885DRD2 2732/4885 |
| US-12421220-B2 | Bicyclic-substituted glutarimide cereblon binders | CRBN, STUB1, CUL1 | PDK2 2244/4885PDK4 2552/4885DRD2 2732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.